We examined whether the use of G-CSF-primed unmanipulated bone marrow (pBM) permits successful transplantation in patients with adverse comorbid pretransplantation conditions. A total of 33 patients at variable risk of AML undergoing allogeneic SCT from an HLA-identical sibling participated. The patients suffered from a variety of treatment-related sequelae before SCT and many cases also featured the presence of major organ dysfunction. The median follow-up duration of patients who were among the overall survivors was 58 months (range, 11À125 months). The median number of CD34 þ cells infused was 3.5 Â 10 6 per kg (range, 0.8À15.6 Â 10 6 per kg). The median number of days for recovery of ANC and platelet count without transfusion was 13 (range, 6À22) and 18 (range, 11À29) days, respectively. Four patients (12%) died due to nonrelapse causes and only one patient developed the same course of infectious complication as before SCT. No particular finding in the context of CMV infection or other post transplant complication was observed. The estimated 10-year overall survival rate was 68%. Our results suggest that the use of pBM allows successful engraftment without increasing complications in patients with various comorbidities before transplantation.
Introduction
Numerous studies have shown that the use of G-CSFprimed PBSCs results in more rapid engraftment than the use of steady-state bone marrow (sBM) stem cells. 1, 2 In addition, allogeneic G-CSF-primed bone marrow (pBM) stem cells appear to be similar to PBSCs in terms of engraftment potential. [3] [4] [5] [6] [7] Overall, allogeneic hematopoietic SCT using pBM results in more rapid engraftment with a lower incidence of chronic GVHD than SCT using PBSCs. [7] [8] [9] However, relatively few studies have reported on other important clinical outcomes of SCT using pBM vs sBM stem cells, such as acute and chronic GVHD, 2 relapse rate, overall survival (OS) and disease-free survival, and no conclusive evidence so far exists that pBM results in improved survival compared to PBSCs or sBM stem cells. Nevertheless, pBM is advantageous as an allogeneic stem cell product because of both the rapidity of PB recovery and the decreased incidence of chronic GVHD compared to SCT using PBSCs. Allogeneic SCT using PBSCs is increasing because it permits enhanced engraftment and the ability to obtain stem cells from donors without the need for general anesthesia; however, this technique is associated with the increased incidence of critical forms of chronic GVHD, without any improvement in speed of engraftment compared to SCT using pBM. To promote rapid engraftment while avoiding detrimental chronic GVHD, several previous studies have investigated megadose SCT using pBM plus PBSCs 10 and high-dose pBM. 5, 6, 8, 11 On the basis of these earlier studies, we investigated the use of pBM in allogeneic sibling SCT under less than optimal conditions. More specifically, we examined the effectiveness of this procedure in cases of inferior donor condition (that is, markedly lower body weight than the recipient) and in recipients exhibiting various clinical comorbidities. We found that the use of pBM is effective in achieving a good quality of life after allogeneic SCT in patients with AML having various pretransplant comorbidities.
Materials and methods

Patients
A total of 33 consecutive patients treated for AML between January 1998 and December 2007 in the Catholic Hemopoietic Stem Cell Transplantation Center were considered eligible for this study if they had an HLA-identical sibling donor. Our center's treatment policy is to perform myeloablative allogeneic SCT in intermediateto high-risk adult patients with AML if an HLA-matched related donor is available. The procedure is performed as soon as possible after the first CR as an intensified postremission therapy. The main clinical characteristics of patients at the time of SCT are summarized in Table 1 .
The median follow-up of patients who were among the overall survivors after allogeneic SCT was 58 months (range, , and a median period of 5 months (range, 4-10) had elapsed between diagnosis and transplant. To investigate the effectiveness of overcoming various pretransplant comorbidities and to monitor transplantation outcomes after SCT using pBM, the same G-CSF-priming protocol and a very similar transplant procedure were applied in patients with a single-disease entity of AML. The most frequent pre-SCT complications were anal or perianal infections, followed by lung infections and chemotherapyrelated cardiomyopathies. Among 33 patients with AML, 19 showed other comorbidities (Table 2) . Separately, a weight disparity of greater than 10 kg between the donor and the recipient (when the recipient weighed more than the donor) was another criterion for enrollment in this study.
As summarized in Table 1 , 30 patients (91%) received transplants in first CR and 3 patients (9%) in second CR. HLA compatibility was determined by serotyping or highresolution genotyping for HLA-A, -B, -C and -DRB1, depending on the method available at the time of SCT. Before 2005, donor identification was based on HLA serotyping for class I antigens (HLA-A, -B and -C) and high-resolution genotyping (PCR with sequence-specific primers, SSP) for class II antigens (HLA-DRB1). Since 2005, all donor-recipient pairs have been genotyped by PCR-SSP for class I and II antigens. All 33 patients in this study received pBM transplants from a fully matched sibling donor. All patients and donors provided written informed consent, and the treatment protocol was approved by the institutional review board of the Catholic University of Korea.
Chemotherapy before SCT Since its introduction in 1996, our center's chemotherapy regimen for AML has undergone several modifications that have been documented in previous publications, [12] [13] [14] [15] and all patients enrolled in this study were treated according to the last updated standard protocol. All patients with AML were subjected to the same induction and consolidation strategy. Briefly, the treatment regimen consisted of '3 Â 7' idarubicin (IDA) plus N4-behenoyl-1-b-D-arabinofuranosyl cytosine (BH-AC) induction chemotherapy (IC). IDA was administered i.v. at a daily dose of 12 mg/m 2 over a period of 30 min for 3 consecutive days, and BH-AC was administered daily at a dose of 300 mg/m 2 over a period of 4 h for 7 consecutive days. On the basis of the results of a BM examination on D þ 7 of chemotherapy (that is, depending on the ratio of the remaining leukemic cells), augmentation treatment was performed if a patient demonstrated more than 5% leukemic blasts. That is, if a patient displayed over 5À10% leukemic blasts in D þ 7 marrow following initial IC, BH-AC was administered at a 
Conditioning regimens and pBM
We performed pBM transplantation using a group of patients with AML in CR, whose clinical conditions are summarized in Table 2 . The majority of patients (N ¼ 27) underwent a myeloablative conditioning regimen consisting of CY (60 mg/kg per day for 2 days) and TBI (total 1320 cGy for 4 days). One patient received BU i.v. (3.2 mg/ kg per day for 4 days) and CY (60 mg/kg per day for 2 days). Uroepithelial prophylaxis was achieved with hyperhydration and mesna. The remaining patients received BU i.v. (3.2 mg/kg per day for 2 days) and fludarabine (30 mg/ m 2 per day for 5 days). pBM stem cells were infused 24 h after the last CY or fludarabine treatment (day 0). For BM expansion with G-CSF priming, the donors received 10 mg/ kg per day G-CSF s.c. for 3 days from DÀ3 to DÀ1, according to our standard protocol. No other treatment, such as ex vivo T-cell depletion of the graft, was performed in any case.
GVHD prophylaxis
In 28 patients, GVHD prophylaxis was provided by administering a continuous i.v. infusion of 3 mg/kg CsA from day 1. Subsequently, when patients were able to tolerate oral administration, they received CsA orally at 6 mg/kg per day in two doses until day 120. Tacrolimus was used in the remaining five patients. The dose of CsA or tacrolimus was then gradually tapered, and in the absence of GVHD, discontinued 6 months after SCT. All patients who received CsA also received a short course of MTX (10 mg/m 2 ) on days 1, 3, 6 and 11; patients who received tacrolimus received the same dose of MTX on day 1, and a reduced dose (5 mg/m 2 ) on days 3, 6 and 11.
General supportive care
All patients were treated in private rooms with laminar airflow and received oral nonabsorbable antibiotics and a low-microbial diet for gut decontamination. Trimethoprim sulfamethoxazole was administered for Pneumocystis carinii prophylaxis. Patients with an ANC of less than 0.5 Â 10 9 per liter and body temperatures exceeding 38.3 1C were empirically treated with broad-spectrum antibiotics. G-CSF (s.c., 5 mg/kg per day) was initiated on the seventh day post-pBM infusion, and continued until ANC reached 1.0 Â 10 9 per liter for 3 consecutive days.
Statistical analysis
For all analyses, Po0.05 was considered statistically significant. OS was calculated from the time of diagnosis to death. Time to relapse was calculated from the date of transplantation until the date of relapse, and the probability of relapse was estimated using the cumulative incidence method. Cumulative incidence of relapse (CIR) was defined based on morphological evidence of leukemia in BM or extramedullary organs. To evaluate the probability of relapse, we excluded patients who died from either direct procedural toxicity or any other cause not related to leukemia. Event-free survival (EFS) was calculated from the date of stem cell infusion until the date of engraftment failure, disease recurrence, secondary malignancy, death from any cause or the last follow-up contact for patients who did not experience any of these events. The Kaplan-Meier method was used to calculate OS and EFS; statistical significance under various clinical conditions was calculated using the log-rank test. Patients who were still alive in CR were censored at the time of their last followup. Nonrelapse mortality (NRM) was defined as death occurring in relapse-free patients. Death resulting from any cause after relapse was considered to have been caused by relapse. Univariate analysis was performed to test for associations between OS/EFS outcomes and the demographic profiles of recipients and donors, subtypes of AML, disease status before transplantation, clinical variables including cytogenetics and conditioning regimens, presence or absence of acute and/or chronic GVHD, stem cell source and infused CD34 þ cell dose by using the Cochran-Mantel-Haenszel test. Factors associated with each clinical parameter at Po0.20 in the univariate analyses were then used in the multivariate Cox proportional hazards regression analysis, using a forward stepwise approach.
Results
Infused cell doses and engraftment
The infused CD34 þ cell doses consisted of a median of 3.5 (0.8-15.6) Â 10 6 per kg CD34 þ cells; the median number of infused CD3
þ cells is shown in Table 3 . The median Abbreviations: MNC ¼ mononuclear cell; pBM ¼ primed bone marrow; TNC ¼ total nucleated cell.
Overcoming various comorbidities pre-SCT H-J Kim et al number of days for the recovery of the ANC to over 500 per ml and platelet count to over 20 000 per ml without transfusion was 13 (6À22) and 18 (11À29) days, respectively. All patients showed successful engraftment.
Survival rate and relapse
The overall 10-year Kaplan-Meier estimated OS and EFS rates were 68 and 62%, respectively (Figures 1 and 2 ). Of 23 patients (70%) who survived, 21 (64%) remained in continuous CR. Among the 10 patients who died, 4 (40%) died of causes other than leukemic relapse. The 10-year CIR was 26% for all patients (Figure 3 ). In the univariate analysis, patient age, patient or donor sex, use of heparin for veno-occlusive disease prophylaxis, infused CD34 þ cell dose, platelet recovery and presence of anal/ perianal or pulmonary infectious sequelae before SCT correlated with OS to the extent of the statistical power, Po0.2 (Table 4 ). In the multivariate analysis, however, only the infused CD34 þ cell dose influenced survival (P ¼ 0.0274). Both patient and donor sex showed a trend of marginal significance, as shown in Table 4 . By contrast, patient sex, infused CD34 þ cell dose, platelet recovery and the development of chronic GVHD were all marginally significant predictors of EFS by multivariate analysis. Furthermore, the presence of the weight disparity between the donor and recipient was not significantly associated with OS or EFS by multivariate analysis. Therefore, neither the presence of pre-SCT comorbidities nor weight disparity was closely related to inferior survival rates in this study. These findings suggest that we can possibly overcome various pre-SCT comorbidities by pBM SCT in adult patients with AML.
Development of acute and chronic GVHD
Of the 33 patients at risk, 14 patients (42%) developed acute GVHD, with 5 patients (15%) exceeding grade I (Table 5) . However, only one patient demonstrated steroidresistant grade III acute GVHD. The incidence of chronic GVHD was 50% (16) of the 32 patients evaluated, which included 5 limited and 11 extensive cases. Notably, 10 cases evolved from acute GVHD (progressive type). Fortunately, we have not experienced any fatal case of chronic GVHD to date. Upon multivariate analysis, the development of acute GVHD was the only statistically significant factor associated with chronic GVHD. Our analysis did not identify any risk factors for the development of acute GVHD or the severity of acute or chronic GVHD (data not shown), which may have been the result of a relatively small sample size. Furthermore, one relapse developed among those who developed a progressive type of chronic GVHD.
NRM
The estimated cumulative incidence of NRM was 15% (4 of 33; Figure 4 ; Table 6 ). Three of these four patients died from pneumonia, two of whom also developed acute respiratory distress syndrome (ARDS). As mentioned above, one patient developed steroid-resistant grade III acute GVHD, which resulted in the patient's death. Furthermore, among 22 cases who had precipitating infectious comorbidities before SCT (for example, pneumonia, hemorrhoid sequelae, viral hepatitis), 3 patients showed aggravation of the same organ condition after SCT. One patient died of cardiopulmonary dysfunction due to pneumonia with precedent chemotherapy-induced cardiomyopathy combined with limited chronic GVHD at 19 months post-SCT. Neither CMV antigenemia nor CMV disease was significantly correlated with the development of GVHD or NRM in this study (data not shown).
Discussion
In general, a high BM or PB cell dose has been shown to enhance engraftment after transplant and reduce TRM in both sibling and alternative donor transplants. [12] [13] [14] Therefore, many recent clinical studies have relied on PBSCs as a cell source in such cases. Some conflicting results have been reported with respect to chronic GVHD before 2000, when we performed G-CSF-mobilized peripheral blood stem cell transplantation (PBSCT). However, a higher incidence of chronic GVHD in PBSCT compared to SCT using sBM may be more acceptable with current management strategies. 1, 2, 8, 9, 15 Moreover, based on a meta-analysis performed in 2001, PBSCT involves a slightly increased risk of acute GVHD. 16 More importantly, recent studies have found no significant difference between PBSCT and SCT using pBM in terms of engraftment, although PBSCT involved a significantly increased risk of acute and/or chronic GVHD. 5, 6, 17 In this study treating the single-disease entity of AML, allogeneic sibling SCT using 3-day pBM showed stable Figure 4 The 10-year cumulative incidence of nonrelapse mortality (NRM) after G-CSF-primed bone marrow (pBM) SCT using HLAmatched sibling donors in patients with AML was 15%, as determined by the Kaplan-Meier method. Table 6 Primary causes of NRM
Cause of death
Pneumonia ± ARDSengraftment and tolerable outcomes, that is, without development of the same course of infectious complications and aggravation of major organ dysfunction as before SCT. Notably, the patients treated here suffered from various pre-SCT comorbidities combined with a weight discrepancy between the donor and recipient. Overall, the 10-year Kaplan-Meier estimated OS and EFS rates were 68 and 62%, respectively. Chronic GVHD developed in 50% of evaluable patients, with a somewhat higher incidence of the extensive type (34%); one patient developed severe acute GVHD (grade III). These results suggest that our pBM strategy may increase the likelihood of chronic GVHD. However, most patients responded well to the conventional management strategy and the overall rate of acute and chronic GVHD was deemed acceptable. One patient, who showed limited chronic GVHD, died of delayed pneumonia with ARDS. Therefore, our results suggest that SCT using pBM may be advantageous in terms of overcoming pretransplant comorbidities. The dose of G-CSF used in this study was 10 mg/kg per day s.c. for 3 consecutive days (that is, DÀ3, DÀ2 and DÀ1). According to the literature, several G-CSF regimens have been used to stimulate BM, ranging from 2-to 5-day priming periods at doses of 3À10 mg/kg per day. [3] [4] [5] [6] 18 Our modified G-CSF regimen was chosen based on previous data indicating that two doses (that is, DÀ2 and DÀ1) produce sufficient CD34 þ and CD3 þ cells to allow rapid engraftment with modest transfusion requirements and a decrease in hospitalization by a mean of 10 days. 3 The CD34 þ and CD3 þ cell contents per kilogram recipient body weight were comparable with values observed in previous studies. 5, 6 As observed in both animal and human studies, G-CSF induces IL-4 and IL-10 production in peripheral T cells (that is, the TH2 lymphokine profile) instead of TH1-polarized proinflammatory cytokines; in addition, G-CSF induces a reduction in the total number of BM T cells and reverses the CD4 þ /CD8 þ ratio. [18] [19] [20] [21] Although some conflicting data have been reported, the majority of studies agree that pBM or sBM SCT reduces the incidence of chronic GVHD compared to PBSCT. 6, 7, 9 Thus, considering both in vitro and clinical findings regarding acute and chronic GVHD, pBM appears to be an appropriate stem cell source for use in patients with critical comorbidities because it is less likely to result in chronic GVHD. However, our data showed that pBM SCT resulted in a tendency to increased rate of progressive-type chronic GVHD, but comparable values for OS and EFS. Unfortunately, we did not examine T-cell subsets during this study, so we are unable to determine any differences in cellular immunologic responses according to the duration of G-CSF priming. Further studies are required to reveal the exact mechanism(s) underlying these unexpected clinical outcomes. We identified a potential predictor of OS-the infused CD34 þ cell dose. Interestingly, patient sex showed a trend of marginal significance to OS/EFS. Of note, neither presence of pre-SCT comorbidities nor weight disparity was closely related to inferior survival rates, as shown in Table 4 . The estimated cumulative incidence of NRM was 15% in this study, even though two-thirds of all patients had prior infectious sequelae with the potential of inducing critical consequences. These findings suggest that we can possibly overcome various pre-SCT comorbidities by higher doses of pBM SCT in adult patients with AML.
In conclusion, our results suggest that a 3-day schedule of pBM is a feasible and reliable method of obtaining sufficient stem cells from allogeneic sibling donors before BM harvest, even in cases in which the recipient weighs more than the donor or suffers from an infectious or noninfectious comorbidity.
